In Vivo Targeting of ADAM9 Gene Expression Using Lentivirus-Delivered shRNA Suppresses Prostate Cancer Growth by Regulating REG4 Dependent Cell Cycle Progression

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Liu, Che Ming ^a   Hsieh, Chia Ling ^a,b,f   He, Yun Chi ^a   Lo, Sen Jei ^a   Liang, Ji An ^b   Hsieh, Teng Fu ^a,c,d   Josson, Sajni ^e   Chung, Leland W K ^e   Hung, Mien Chie ^a,b,f,g   Sung, Shian Ying ^a,b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f ASIA UNIVERSITY   (Taiwan)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM9 PROTEIN; BINDING PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; LENTIVIRUS VECTOR; METALLOPROTEINASE; REGENERATING ISLET DERIVED FAMILY MEMBER 4; SHORT HAIRPIN RNA; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM;

ADAM PROTEINS; ANDROGENS; ANIMALS; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GENETIC THERAPY; HUMANS; LECTINS, C-TYPE; LENTIVIRUS; MALE; MEMBRANE PROTEINS; MICE; MOLECULAR TARGETED THERAPY; OSTEOLYSIS; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; S PHASE CELL CYCLE CHECKPOINTS;

LENTIVIRUS; MURINAE;

EID: 84872448443     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053795     Document Type: Article

References (48)

1. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, et al. (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31: 578-583.
2. McMurtry CT, McMurtry JM, (2003) Metastatic prostate cancer: complications and treatment. J Am Geriatr Soc 51: 1136-1142.
3. Villavicencio H, (1993) Quality of life of patients with advanced and metastatic prostatic carcinoma. Eur Urol 24Suppl 2: 118-121.
4. Coleman WB, Tsongalis GJ, (1995) Multiple mechanisms account for genomic instability and molecular mutation in neoplastic transformation. Clin Chem 41: 644-657.
5. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, et al. (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26: 242-245.
6. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, et al. (2009) Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 27: 5431-5438.
7. Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, et al. (2005) Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65: 8455-8460.
8. Fischer OM, Hart S, Gschwind A, Prenzel N, Ullrich A, (2004) Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol Cell Biol 24: 5172-5183.
9. Hotoda N, Koike H, Sasagawa N, Ishiura S, (2002) A secreted form of human ADAM9 has an alpha-secretase activity for APP. Biochem Biophys Res Commun 293: 800-805.
10. Izumi Y, Hirata M, Hasuwa H, Iwamoto R, Umata T, et al. (1998) A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. Embo J 17: 7260-7272.
11. Mahimkar RM, Visaya O, Pollock AS, Lovett DH, (2005) The disintegrin domain of ADAM9: a ligand for multiple beta1 renal integrins. Biochem J 385: 461-468.
12. Singh B, Schneider M, Knyazev P, Ullrich A, (2009) UV-induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines. Int J Cancer 124: 531-539.
13. Sung SY, Kubo H, Shigemura K, Arnold RS, Logani S, et al. (2006) Oxidative Stress Induces ADAM9 Protein Expression in Human Prostate Cancer Cells. Cancer Res 66: 9519-9526.
14. Fritzsche FR, Jung M, Tolle A, Wild P, Hartmann A, et al. (2008) ADAM9 Expression is a Significant and Independent Prognostic Marker of PSA Relapse in Prostate Cancer. Eur Urol 54: 1097-1108.
15. Pen CC, Liu CM, Lin CC, Lin CC, Hsieh TF, et al. (2012) Combined dynamic alterations in urinary VEGF levels and tissue ADAM9 expression as markers for lethal phenotypic progression of prostate cancer. Chin J Physiol 55: E-pub ahead of print; DOI: 10.4077/CJP.2012.BAA075.
16. Josson S, Anderson CS, Sung SY, Johnstone PA, Kubo H, et al. (2011) Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy. Prostate 71: 232-240.
17. Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, et al. (2008) Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res 68: 9996-10003.
18. Ormerod MG (2000) Flow Cytometry: a practical approach; Ormerod MG, editor: Oxford University Press.
19. Shigemura K, Sung SY, Kubo H, Arnold RS, Fujisawa M, et al. (2007) Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate 67: 722-731.
20. Vanderlaag K, Wang W, Fayadat-Dilman L, Wagner J, Bald L, et al. (2012) Regenerating islet-derived family member, 4 modulates multiple receptor tyrosine kinases and mediators of drug resistance in cancer. Int J Cancer 130: 1251-1263.
21. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512.
22. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520.
23. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995-2005.
24. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, et al. (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375: 1437-1446.
25. Smith MR, (2004) The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy. Oncology (Williston Park) 18: 21-25.
26. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, et al. (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377: 813-822.
27. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422.
28. Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, et al. (2007) Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13: 3883-3891.
29. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, et al. (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28: 1099-1105.
30. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, et al. (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379: 39-46.
31. Cao DX, Qiao B, Ge ZQ, Yuan YJ, (2004) Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett 214: 103-113.
32. Mizumachi T, Suzuki S, Naito A, Carcel-Trullols J, Evans TT, et al. (2008) Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells. Oncogene 27: 831-838.
33. Franzke CW, Bruckner-Tuderman L, Blobel CP, (2009) Shedding of collagen XVII/BP180 in skin depends on both ADAM10 and ADAM9. J Biol Chem 284: 23386-23396.
34. Fry JL, Toker A, (2010) Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration. Cancer Res 70: 8187-8198.
35. Kuo PL, Huang MS, Cheng DE, Hung JY, Yang CJ, et al. (2012) Lung Cancer-derived Galectin-1 Enhances Tumorigenic Potentiation of Tumor-associated Dendritic Cells by Expressing Heparin-binding EGF-like Growth Factor. J Biol Chem 287: 9753-9764.
36. Trachootham D, Alexandre J, Huang P, (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591.
37. Ip SW, Liao SS, Lin SY, Lin JP, Yang JS, et al. (2008) The role of mitochondria in bee venom-induced apoptosis in human breast cancer MCF7 cells. In Vivo 22: 237-245.
38. Zhang Y, Lai M, Gu X, Luo M, Shao L, (2003) Reg IV, a differentially expressed gene in colorectal adenoma. Chin Med J (Engl) 116: 918-922.
39. Takehara A, Eguchi H, Ohigashi H, Ishikawa O, Kasugai T, et al. (2006) Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci 97: 1191-1197.
40. Tamura H, Ohtsuka M, Washiro M, Kimura F, Shimizu H, et al. (2009) Reg IV expression and clinicopathologic features of gallbladder carcinoma. Hum Pathol 40: 1686-1692.
41. Violette S, Festor E, Pandrea-Vasile I, Mitchell V, Adida C, et al. (2003) Reg IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas. Int J Cancer 103: 185-193.
42. Moon JH, Fujiwara Y, Nakamura Y, Okada K, Hanada H, et al. (2012) REGIV as a potential biomarker for peritoneal dissemination in gastric adenocarcinoma. J Surg Oncol 105: 189-194.
43. Gu Z, Rubin MA, Yang Y, Deprimo SE, Zhao H, et al. (2005) Reg IV: a promising marker of hormone refractory metastatic prostate cancer. Clin Cancer Res 11: 2237-2243.
44. Hayashi T, Matsubara A, Ohara S, Mita K, Hasegawa Y, et al. (2009) Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker. Oncol Rep 21: 95-100.
45. Ohara S, Oue N, Matsubara A, Mita K, Hasegawa Y, et al. (2008) Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer. Cancer Sci 99: 1570-1577.
46. Kuniyasu H, Oue N, Sasahira T, Yi L, Moriwaka Y, et al. (2009) Reg IV enhances peritoneal metastasis in gastric carcinomas. Cell Prolif 42: 110-121.
47. Rafa L, Dessein AF, Devisme L, Buob D, Truant S, et al. (2010) REG4 acts as a mitogenic, motility and pro-invasive factor for colon cancer cells. Int J Oncol 36: 689-698.
48. Nanakin A, Fukui H, Fujii S, Sekikawa A, Kanda N, et al. (2007) Expression of the REG IV gene in ulcerative colitis. Lab Invest 87: 304-314.